Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001438533-26-000027
Filing Date
2026-04-06
Accepted
2026-04-06 16:07:43
Documents
18
Period of Report
2026-05-19

Document Format Files

Seq Description Document Type Size
1 DEF 14A tvtx-20260404.htm   iXBRL DEF 14A 1441765
3 GRAPHIC tvtx-20260404_g1.jpg GRAPHIC 300529
4 GRAPHIC tvtx-20260404_g2.jpg GRAPHIC 254659
5 GRAPHIC tvtx-20260404_g3.jpg GRAPHIC 242799
6 GRAPHIC tvtx-20260404_g4.jpg GRAPHIC 1020
7 GRAPHIC tvtx-20260404_g5.jpg GRAPHIC 915
8 GRAPHIC tvtx-20260404_g6.jpg GRAPHIC 889
  Complete submission text file 0001438533-26-000027.txt   4133291

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tvtx-20260404.xsd EX-101.SCH 922
21 EXTRACTED XBRL INSTANCE DOCUMENT tvtx-20260404_htm.xml XML 147667
Mailing Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130
Business Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130 888-969-7879
Travere Therapeutics, Inc. (Filer) CIK: 0001438533 (see all company filings)

EIN.: 262383102 | State of Incorp.: CA | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36257 | Film No.: 26841245
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)